Contrary to a few studies that earlier suggested benefits from an arthritis drug for patients with severe or critical Covid-19 infection, a new study indicates that it is not better than standard care alone.
According to the researchers, including Regis G Rosa from Hospital Moinhos de Vento in Brazil, there was an increased number of deaths at 15 days in patients receiving an arthritis drug — tocilizumab — that resulted in the trial being stopped early.
Follow NewsGram on Twitter to stay updated about the World news.
These results contradict earlier observational studies suggesting a benefit of tocilizumab. However, observational effects are limited by a high risk that they may be due to other unknown (confounding) factors — and some studies have not yet been peer-reviewed or published in a medical journal, the researchers said in a paper published in The BMJ journal.
An increased number of deaths at 15 days in patients receiving an arthritis drug. PIxabay
Tocilizumab blocks a specific part of the immune system (interleukin 6) that can go into overdrive in some patients with Covid-19. According to the team, doctors think this might help lessen the body's inflammatory response to the virus and avert some of the more dire consequences of the disease, but its effects are not well defined.
To test this theory, researchers conducted a randomized controlled trial involving 129 Covid-19 patients with an average age of 57 years and compared tocilizumab plus standard care with standard care alone. Patients were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two chemicals linked to inflammation in their blood.
The study participants have randomly divided into two groups — 65 received tocilizumab plus standard care and 64 received standard care alone. All patients were monitored for 15 days. By day 15, 18 (28 percent) patients in the tocilizumab group and 13 (20 percent) in the standard care group were receiving mechanical ventilation or had died. Death at 15 days occurred in 11 (17 percent) patients in the tocilizumab group compared with 2 (3 percent) in the standard care group. (IANS)